Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Daxor Corp's Score
Industry at a Glance
Industry Ranking
28 / 30
Overall Ranking
544 / 4682
Industry
Collective Investments
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
23.500
Target Price
+82.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Daxor Corp Highlights
StrengthsRisks
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.22M.
Overvalued
The company’s latest PB is 1.60, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.09K shares, decreasing 11.19% quarter-over-quarter.
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Ticker SymbolDXR
CompanyDaxor Corp
CEOFeldschuh (Michael Richard)
Websitehttps://www.daxor.com/
FAQs
What is the current price of Daxor Corp (DXR)?
The current price of Daxor Corp (DXR) is 12.895.
What is the symbol of Daxor Corp?
The ticker symbol of Daxor Corp is DXR.
What is the 52-week high of Daxor Corp?
The 52-week high of Daxor Corp is 14.150.
What is the 52-week low of Daxor Corp?
The 52-week low of Daxor Corp is 6.550.
What is the market capitalization of Daxor Corp?
The market capitalization of Daxor Corp is 64.27M.
What is the net income of Daxor Corp?
The net income of Daxor Corp is 536.33K.
Is Daxor Corp (DXR) currently rated as Buy, Hold, or Sell?
According to analysts, Daxor Corp (DXR) has an overall rating of Buy, with a price target of 23.500.
What is the Earnings Per Share (EPS TTM) of Daxor Corp (DXR)?
The Earnings Per Share (EPS TTM) of Daxor Corp (DXR) is 0.348.